

#### REMARKS

New Claims 82-101 have been added. Support for Claims 82, 87-88, 91-92, and 95 may be found in the specification, for example, in paragraphs 0006 and 0035. The Applicants note that N-desmethylclozapine is inherently a muscarnic M1 receptor ectopic activator that acts at a different site than the orthosteric site of the muscarinic M1 receptor, a muscarinic M1 receptor ectopic agonist, and a non-peptidal muscarinic M1 receptor ectopic activator. Support for Claims 83 and 96 may be found in the specification, for example, in paragraph 0030. Support for Claims 84, 94, 97, and 101 may be found in the specification, for example, in paragraph 0032. Support for Claims 85 and 98 may be found in the specification, for example, in paragraph 0031. Support for Claims 86 and 99 may be found in the specification, for example, in Table 2. Support for Claim 89 may be found in the specification, for example, in Tables 1 and 2. Support for Claim 90 may be found in the specification, for example, in paragraphs 0038-0041. Support for Claims 93 and 100 may be found in the specification, for example, in paragraphs 0024 and 0032.

Claims 1-9 and 59-101 are pending. No new matter has been added by the above amendments.

Applicants note that new Claims 82-101 provided herein are for the same or substantially the same subject matter as claims 1-2, 4-5, 7-9, 13-17, and 19-20 of the '767 Application published as Publication No. 2006/0233843 on October 19, 2006. These claims are being submitted before one year after the date on which the '767 Application published.

No fees are believed due; however, please charge any fees, including any fees for extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 18-Oct-07

By: 

Kerry Taylor  
Registration No. 43,947  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550